Die Leipziger Biotechnologie Firma c-LEcta blickt auf ein erfolgreiches Geschäftsjahr zurück: Das Finanzjahr 2016 konnte mit einem Gewinn abgeschlossen werden. Seit 2014 erwirtschaftet c-LEcta ein positives, operatives Ergebnis und gehört damit zu den wenigen Ausnahmen unter den Firmen in der Biotech-Branche. Damit fühlt c-LEcta sich in ihrer Geschäftsstrategie bestätigt und wird weiterhin darauf bauen, Wachstum über die Entwicklung eigener, innovativer Produktideen zu realisieren.

The industrial biotechnology company c-LEcta is looking back on another successful business year: The financial year 2016 could be closed with a profit on earnings. Since 2014 the company generates positive operational results and thereby stands out from many other companies in the biotech sector. It confirms c-LEcta’s business strategy and reinforces the company in following its promising product-driven growth path.

”We are happy to announce another successful financial year. Reaching our financial targets and at the same time investing into our product pipeline from internal cash-flow is very important for the overall development aims of c-LEcta.” says Carsten Fietz, Head of Finance and Administration, with respect to the financial data of business year 2016.

“Our reliable industrial partners for joint product developments and the market success of our already launched products allow us to invest into high-potential new product developments. Such products were very successfully developed in the last three years and we are now on the way to introduce them into the market. This will allow us to continue our product-driven growth story”, adds Marc Struhalla, founder and CEO of c-LEcta.

Quelle: Pressemitteilung der c-LEcta GmbH vom 06.07.2017